We have previously demonstrated that interleukin-17A (IL-17) producing T helper 17 cells are significantly elevated in blood and bone marrow (BM) in multiple myeloma (MM) and IL-17A promotes MM ...

Immunotherapy. 2013;5(9):923-925. Rather than focusing on the blockade of IL-17A or IL-17F alone, Wedebye Schmidt et al. examined the effects of blockade of both IL-17A and IL-17F. They report ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx (Bimzelx) for various inflammatory conditions, highlighting its 5 FDA approvals ...

Alumis is also developing another tyrosine kinase 2 blocker, A-005, for neuroinflammatory and neurodegenerative conditions ...

The company said Bimzelx is now the first IL-17A and IL-17F inhibitor approved for the condition. Bimzelx is also FDA approved for the treatment of plaque psoriasis, psoriatic arthritis ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing in diagnostic substances with a market ...

在1月20日，令人振奋的消息传来，智翔金泰的1类新药赛立奇单抗（GR1501注射液）新适应症正式在国内获批上市，这款药物专门用于治疗放射学阳性中轴型脊柱关节炎，大家熟知的强直性脊柱炎患者有救了！

MoonLake Immunotherapeutics (MLTX) announced that patients have been screened in three new trials across three new indications to evaluate ...

The following is a summary of “Biomarkers of oxidation, inflammation and intestinal permeability in persons with diabetes mellitus with parenteral nutrition: A multicenter randomized trial,” published ...